2013
Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients
Kirst M, Li E, Wang C, Dong H, Liu C, Fried M, Nelson D, Wang G. Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients. PLOS ONE 2013, 8: e69698. PMID: 23922778, PMCID: PMC3726766, DOI: 10.1371/journal.pone.0069698.Peer-Reviewed Original ResearchConceptsResistance-associated variantsProtease inhibitorsChronic HCV infectionLiver transplant recipientsHCV drug resistanceFuture therapeutic strategiesHCV protease inhibitorsMutation linkageHigh-level resistanceLow levelsPI monotherapyTransplant recipientsHCV infectionLiver transplantLiver transplantationAntiviral therapyHCV populationTherapeutic strategiesViral variantsDrug resistanceDecreased susceptibilityQuasispecies populationPatientsDominant variantDeep sequencing analysis
2012
CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Firpi R, Dong H, Clark V, Soldevila‐Pico C, Morelli G, Cabrera R, Norkina O, Shuster J, Nelson D, Liu C. CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International 2012, 33: 72-78. PMID: 23107586, PMCID: PMC3518691, DOI: 10.1111/liv.12013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsBiopsyFemaleFloridaGenotypeHepatitis CHumansInterferonsInterleukinsKaplan-Meier EstimateLiver CirrhosisLiver TransplantationLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsTreatment OutcomeConceptsSustained viral responseInterferon-based therapyLiver transplant patientsCC genotypeRecurrent HCVLiver transplantTransplant patientsIL-28B single nucleotide polymorphismInterleukin (IL) 28B single nucleotide polymorphismsAdult liver transplant patientsPost-transplant HCV recurrenceHepatitis C populationIL-28B genotypeIL-28B polymorphismsInterleukin 28B (IL28B) polymorphismsStrongest pretreatment predictorOverall clinical outcomeBetter treatment responseSingle nucleotide polymorphismsHCV recurrenceHCV patientsHCV therapyLiver transplantationHepatitis COverall survivalHistopathologic Resolution of Adult Liver Transplantation Adenovirus Hepatitis With Cidofovir and Intravenous Immunoglobulin: A Case Report
Kerensky T, Hasan A, Schain D, Trikha G, Liu C, Rand K, Soldevila-Pico C, Gupte A. Histopathologic Resolution of Adult Liver Transplantation Adenovirus Hepatitis With Cidofovir and Intravenous Immunoglobulin: A Case Report. Transplantation Proceedings 2012, 45: 293-296. PMID: 23267812, DOI: 10.1016/j.transproceed.2012.06.059.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsTransplant recipientsHistopathologic resolutionFatal outcomeAdult solid organ transplant recipientsAdult liver transplant recipientsAdult renal transplant recipientsClearance of viremiaCombination of cidofovirPatient's fatal outcomeLiver transplant recipientsRenal transplant recipientsLiver biopsy specimenSpecific treatment modalitiesPositive immunohistochemical stainingAdV diseaseIntravenous cidofovirIntravenous immunoglobulinAdenovirus hepatitisCombination therapyBiopsy specimenCase reportTreatment modalitiesPolymerase chain reaction
2011
Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience
Pan J, Oh S, Soldevila‐Pico C, Nelson D, Liu C. Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience. Clinical Transplantation 2011, 25: 164-170. PMID: 20156222, PMCID: PMC3480317, DOI: 10.1111/j.1399-0012.2010.01211.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCase-Control StudiesDNA, ViralFemaleFollow-Up StudiesGraft SurvivalHepatitis BHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansImmunoenzyme TechniquesLiver TransplantationMaleMiddle AgedPolymerase Chain ReactionPrevalenceRetrospective StudiesSurvival RateTissue DonorsTransplantation, HomologousTreatment OutcomeVirus ActivationConceptsHepatitis B virusDetectable HBV DNAHBV DNALiver allograftsLow prevalenceDe novo hepatitis B.Serum HBV DNA levelsHepatitis B core antigenHepatitis B surface antigenHBV DNA levelsSingle-center experienceB core antigenLiver biopsy tissueB surface antigenViral protein expressionHBV serologySeronegative recipientsHBV infectionHepatitis B.Such prophylaxisPositive donorsCore antigenRetrospective studyB virusProphylaxis
2006
Betaine Resolves Severe Alcohol-Induced Hepatitis and Steatosis Following Liver Transplantation
Samara K, Liu C, Soldevila-Pico C, Nelson D, Abdelmalek M. Betaine Resolves Severe Alcohol-Induced Hepatitis and Steatosis Following Liver Transplantation. Digestive Diseases And Sciences 2006, 51: 1226-1229. PMID: 16944015, DOI: 10.1007/s10620-006-8038-3.Peer-Reviewed Original Research
2005
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
Firpi R, Zhu H, Morelli G, Abdelmalek M, Soldevila‐Pico C, Machicao V, Cabrera R, Reed A, Liu C, Nelson D. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplantation 2005, 12: 51-57. PMID: 16382464, DOI: 10.1002/lt.20532.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsSustained virological responseVirological responseTransplant recipientsCombination of cyclosporineInterferon-based therapyCombination of interferonEffect of cyclosporineDose-dependent mannerAnti-viral potentialLiver transplantationHistologic diseaseImmunosuppressive agentsViral clearanceHerpes simplexC virusAntiviral effectCyclosporine inhibitsCyclosporineTherapyViral replicationAntiviral activityTacrolimusInterferonReplicon system
2004
One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplantSustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Abdelmalek M, Firpi R, Soldevila‐Pico C, Reed A, Hemming A, Liu C, Crawford J, Davis G, Nelson D. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 2004, 10: 199-207. PMID: 14762857, DOI: 10.1002/lt.20074.Peer-Reviewed Original ResearchConceptsHepatitis C virusLiver transplant recipientsTransplant recipientsHepatitis CLiver histologyFibrosis stageHCV RNAViral clearanceViral responseCombination therapyDetectable hepatitis C virusRecurrent chronic hepatitis CRecurrent hepatitis C infectionRecurrent hepatitis C virusDetectable HCV RNASustained viral responseChronic hepatitis CInterferon-based treatmentOrthotopic liver transplantationRecurrent hepatitis CHepatitis C infectionInterferon-based therapyRegression of fibrosisGrade of inflammationBaseline histology
2002
Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
Firpi R, Abdelmalek M, Soldevila‐Pico C, Reed A, Hemming A, Howard R, van der Werf W, Lauwers G, Liu C, Crawford J, Davis G, Nelson D. Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplantation 2002, 8: 1000-1006. PMID: 12424712, DOI: 10.1053/jlts.2002.34968.Peer-Reviewed Original ResearchConceptsInterferon alfa-2bLiver transplantationAlfa-2bHistological recurrenceViral eradicationHCV RNAWeek 24Recurrent hepatitis C virus (HCV) infectionHCV RNA 6 monthsHepatitis C virus infectionEnd pointProgressive cholestatic diseaseRecurrent HCV infectionSerum HCV RNAC virus infectionLiver transplant recipientsPrimary end pointRecurrent hepatitis CSecondary end pointsGenotype 1 infectionYears of therapyEnd of treatmentHigh viral loadLiver biopsy resultsRecurrent HCV